Table 2.
Primary and Secondary Endpoint Components for all Four Factorial Groups
| EDTA Chelation and High-Dose Vitamins (N=421) | EDTA Chelation and Placebo Vitamins (N=418) | Placebo Infusions and High-dose Vitamins (N=432) | Placebo Infusions and Placebo Vitamins (N=437) | P-value* | |
|---|---|---|---|---|---|
| Primary Endpoint | |||||
| All-cause mortality, myocardial infarction, stroke, coronary revascularization or hospitalization for angina | 108 (26%) | 114 (27%) | 122 (28%) | 139 (32%) | 0.016 |
| Death | 43 (10%) | 44 (11%) | 44 (10%) | 49 (11%) | 0.490 |
| Myocardial infarction | 23 (5%) | 29 (7%) | 35 (8%) | 32 (7%) | 0.207 |
| Stroke | 4 (1%) | 6 (1%) | 4 (1%) | 9 (2%) | 0.161 |
| Coronary revascularization | 60 (14%) | 70 (17%) | 72 (17%) | 85 (19%) | 0.017 |
| Hospitalization for angina | 6 (1%) | 7 (2%) | 6 (1%) | 12 (3%) | 0.147 |
| Secondary Endpoint | |||||
| Cardiovascular death, myocardial infarction or stroke | 39 (9%) | 57 (14%) | 55 (13%) | 58 (13%) | 0.045 |
| Cardiovascular death | 19 (5%) | 31 (7%) | 26 (6%) | 25 (6%) | 0.355 |
*
Log-rank 1 df p-values. This is a comparison of the active-active vs. placebo-placebo cells only.